Executive Profiles

Jennifer Buell, chief operating officer at Agenus, discusses the need for additional immunotherapies and combination strategies in cancer-building on learnings from the first wave of immune checkpoint inhibitors.

Tina Tianning Yu, Chief Executive Officer of Mevion Medical Systems, talks about engaging with China's pharma market and laying the foundations for success in 2020 and beyond.

French independent pharma Servier Group, led by president Olivier Laureau, is uniquely positioned to capitalize on new opportunities for expansion and stay true to its R&D and patient-focused mission.

Corey McCann, president and CEO of Pear Therapeutics, discusses how the prescription digital therapeutics space has evolved in a decade from disruptive concept to an exciting, growing market.

Pharm Exec speaks to Katya Svoboda, Taneesha Chawla, and Tanvi Ahuja about the growing practice of applying AI and machine learning in value-based and outcomes-based contracts.

Bernhardt Zeiher, Chief Medical Officer of Astellas discusses how the company transitioned from a traditional R&D approach to a platform approach, the need for innovation models to change in pharma, and the impact academia has on drug development.

Dr. Chris Cutie, chief medical officer of TARIS Bio, discusses his focus on creating new therapies for the often-misunderstood bladder disease population.

William Golden, founder, chairman and CEO of Noveome Biotherapeutics, talks about the potential of the company's lead product, ST266.

Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.

In this Q&A, VP of Crisis Intelligence at Crisp discusses potential crisis points for the pharmaceutical industry.

Leela Barham talks to Sir David Haslam, the outgoing Chair of UK’s National Institute for Health and Care Excellence (NICE), about the highs and lows of his six-year tenure at the organization.

Pharm Exec speaks with Geoff MacKay, co-founder and CEO of AVROBIO, about the company’s mission to advance potentially curative lentiviral-based gene therapies, his career building businesses and innovation in regenerative medicine, and his most important quest to date-moving gene therapy into the mainstream.

Pharm Exec highlights a recent fireside chat between Veeva’s Matt Wallach and Jeffrey Marrazzo, CEO of Luxturna maker Spark Therapeutics.

Matthias Wernicke, General Manager of Merck KGaA’s Biopharma business in Russia, talks about how the country is transitioning from an emerging to a mature pharmaceutical market.

How one company’s cultural transformation aims to strengthen and empower its talent base.

Cell One Partners' George Goldberger discusses the issues that new and emerging cell and gene therapy companies face on the road to commercialisation.

See Li Lynn, LEO Pharma’s HR Manager, South Asia, talks about how LEO is managing the compliance challenges in Asia.

Jan Lichtenberg, Ph.D, and Scott Friedman, MD, talk about the growing interest in nonalcoholic steatohepatitis (NASH) in the pharma industry, the complexities of modeling the disease, and what this means for drug development efforts.

Bruno Wohlschlegel, European head of Merck KGaA, Darmstadt, Germany's Healthcare business, outlines the highlights of his career and talks about how his vision for Europe draws strength from the region’s diversity to advance collaboration and progress.

Gabe Musso, Chief Scientific Officer of BioSymetrics, talks about insights around how AI and ML are being used in biopharma.

Chris Round, Head of International Operations & Global Core Franchises at Merck KGaA, Darmstadt, Germany talks to Pharm Exec about how the company's new treatments are positioned to advance the company’s “double mission."

Pair of interviews spotlight the changing dynamics for C-suite business managers in two contrasting life sciences settings-big, established pharma and small, aggressive biotech.

Esperion CFO Rick Bartram highlights his involvement in the young organization's success over the last six years and discusses the company mission means to him.

Travis Mickle, CEO of KemPharm, talks about his company’s use of prodrugs, the business opportunities prodrugs represent, and how prodrugs are helping to improve patient centricity.

A discussion with Pam Cheng, executive vice president of Operations, Technology at AstraZeneca about making the transition into a Fortune 500 C-Suite role and leadership advice for success.